… as Adjuvant Treatment for Patients at High Risk of Recurrence of Renal Cell Carcinoma …
an improvement in DFS from 1 year of adjuvant treatment with sunitinib, but at the cost of …

… therapies with immunotherapy, neoadjuvant approaches and patient selection will be key to
determining optimal adjuvant therapy … weakness of the five adjuvant antiangiogenic TKI trials…

… no adjuvant therapies in routine clinical use which reliably improve outcomes. Effective
adjuvant therapy … Early efforts explored chemotherapy, radiotherapy, cytokine therapy, hormonal …

… In conclusion, immune therapy has no proven role in adjuvant therapy of RCC. Future
autologous vaccine trials will need to be conservatively reported with the intention-to-treat analysis …

… of targeted agents as adjuvant therapy, which have unfortunately … the main clinical trials
investigating adjuvant therapy in RCC, … is overexpressed in clear cell renal cell carcinoma and is …

… This work provides an overview of current and ongoing trials of adjuvant (postoperative)
therapy for localized renal cell carcinoma. Currently, the gold standard in this disease setting is …

… adjuvant setting or being considered for future adjuvant trials. Here, we discuss the past,
present, and future of adjuvant therapy … high risk for relapse following definitive surgical therapy. …

… agents as adjuvant therapy for renal cell carcinoma (RCC). Advanced RCC is refractory to
… cytotoxic chemotherapy, and clinical trials of adjuvant cytokine therapy in this therapeutic …

… As much as we hoped for a more positive outcome for the use of adjuvant VEGF-targeted
TKIs in renal-cell carcinoma, the benefit for patients that will result from this study by Haas and …

… Therefore, studies have been undertaken to determine whether adjuvant therapy offers a …
Postoperative adjuvant therapies, eg radiation, hormonal therapy, and nonspecific cytokine …